# US 2020/0393469 A1 · Method for determining eligibility of brain tumor patient for tailor-made type peptide vaccine agent

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0393469 A1
- Document ID: US20200393469A1
- Status: Published application
- Kind: A1
- Application number: 16/613,177
- Filed: 2018-05-16
- Published: 2020-12-17
- Earliest claimed: 2017-05-16
- Assignees: Kurume University
- Applicants: Kurume University
- Inventors: Kyogo ITO; Shigeki SHICHIJO
- Web page: https://patentgrep.com/patent/US20200393469A1

## CPC

- G01N 33/57557: {of other specific parts of the body, e.g. brain}
- G01N 33/68: involving proteins, peptides or amino acids {(involving lipoproteins G01N33/92)}
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 35/00: Antineoplastic agents
- A61P 37/04: Immunostimulants
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 7/06: having 5 to 11 amino acids
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- G01N 2800/60: Complex ways of combining multiple protein biomarkers for diagnosis
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Provided are a method for determining whether a subject suffering from a brain tumor is an eligible person for a tailor-made peptide vaccine composition including at least one peptide antigen, a kit used in the aforesaid determination method, and a method for treating a subject suffering from a brain tumor by administering a tailor-made peptide vaccine composition including at least one peptide antigen.

## Claims

### Claim 1

A method for determining whether a subject suffering from a brain tumor is an eligible person for a peptide vaccine composition including at least one peptide antigen, comprising:
evaluating a risk of the subject with respect to the peptide vaccine composition to obtain an evaluation; and
determining whether the subject is an eligible person for the peptide vaccine composition based on the evaluation to obtain a determination,
wherein obtaining the evaluation comprises using at least one prognostic factor selected from the group consisting of GM-CSF, at least one SART2, MCP-1, VEGF, IL-6, IL-7, IL-10, IL-17, IL-1RA, CCL4, and haptoglobin.

### Claim 2 (depends on 1)

The determination method according to claim 1, wherein the at least one prognostic factor includes at least one selected from GM-CSF, the at least one SART2, and MCP-1.

### Claim 3 (depends on 1)

The determination method according to claim 1, wherein the at least one prognostic factor includes at least two selected from the group.

### Claim 4 (depends on 1)

The determination method according to claim 1, wherein obtaining the evaluation comprises
evaluating a risk of the subject with respect to the peptide vaccine composition by comparing a level of granulocyte-macrophage colony-stimulating factor (GM-CSF) in a blood sample from the subject with a GM-CSF threshold to obtain an evaluation A; and further comprises
either one or both of evaluating a risk of the subject with respect to the peptide vaccine composition by comparing an immunoreactivity of the subject to the at least one SART2 peptide with a SART2 threshold to obtain an evaluation B and evaluating a risk of the subject with respect to the peptide vaccine composition by comparing a level of Monocyte Chemoattractant Protein-1 (MCP-1) in a blood sample from the subject with a MCP-1 threshold to obtain an evaluation C;
wherein the evaluation A is given as “having no risk” when the GM-CSF level is less than the GM-CSF threshold, or is given as “having a risk” when the GM-CSF level is not less than the GM-CSF threshold,
the evaluation B is given as “having no risk” when the immunoreactivities of the subject to both of the at least one SART2 peptide are less than the SART2 threshold, or is given as “having a risk” when the immunoreactivity of the subject to any one of the at least one SART2 peptide is not less than the SART2 threshold, and
in the case where the MCP-1 threshold includes an MCP-1 threshold (1), the evaluation C is given as “having a risk” when the MPC-1 level is less than the MCP-1 threshold (1); or in the case where the MCP-1 threshold includes an MCP-1 threshold (1) and an MCP-1 threshold (2) that is greater than the value of the MCP-1 threshold (1), the evaluation C is given as “having no risk” when the MCP-1 level is not less than the MCP-1 threshold (1) and is less than the MCP-1 threshold (2); or is given as “having a risk” when the MCP-1 level is less than the MCP-1 threshold (1) or not less than the MCP-1 threshold (2).

### Claim 5 (depends on 4)

The determination method according to claim 4, wherein the determination is given that the subject is an “eligible person” for the peptide vaccine composition,
when obtaining the evaluation comprises obtaining the evaluation A and obtaining the evaluation B, and either one or both of the evaluation A and the evaluation B are given as “having no risk”; or
when obtaining the evaluation comprises obtaining the evaluation A and obtaining the evaluation C, and either one or both of the evaluation A and the evaluation C are given as “having no risk”.

### Claim 6 (depends on 4)

The determination method according to claim 4, wherein the determination is given that the subject is an “ineligible person” for the peptide vaccine composition,
when obtaining the evaluation comprises obtaining the evaluation A and obtaining the evaluation B, and both of the evaluation A and the evaluation B are given as “having a risk”;
when obtaining the evaluation comprises obtaining the evaluation A and obtaining the evaluation C, and both of the evaluation A and the evaluation C are given as “having a risk”; or
when obtaining the evaluation comprises obtaining the evaluation A, obtaining the evaluation B, and obtaining the evaluation C, and the evaluation A, the evaluation B, and the evaluation C are all given as “having a risk”.

### Claim 7 (depends on 5)

The determination method according to claim 5, wherein the at least one SART2 peptide includes either one or both of SART2-93 peptide (SEQ ID NO:1) and SART2-161 peptide (SEQ ID NO:9).

### Claim 8 (depends on 1)

The determination method according to claim 1, wherein
the subject is HLA-A24 positive;
the peptide vaccine composition includes at least two peptide antigens selected from the peptide antigen group containing SART2-93 peptide (SEQ ID NO:1), SART3-109 peptide (SEQ ID NO:2), Lck-208 peptide (SEQ ID NO:3), PAP-213 peptide (SEQ ID NO:4), PSA-248 peptide (SEQ ID NO:5), EGF-R-800 peptide (SEQ ID NO:6), MRP3-503 peptide (SEQ ID NO:7), MRP3-1293 peptide (SEQ ID NO:8), SART2-161 peptide (SEQ ID NO:9), Lck-486 peptide (SEQ ID NO:10), Lck-488 peptide (SEQ ID NO:11), PSMA-624 peptide (SEQ ID NO:12), EZH2-735 peptide (SEQ ID NO:13) and PTHrP-102 peptide (SEQ ID NO:14), and
the at least two peptide antigens are selected in the descending order of immunoreactivities of the subject to the peptide antigens.

### Claim 9 (depends on 1)

The determination method according to claim 1, wherein the brain tumor is glial tumor or glioma.

### Claim 10 (depends on 9)

The determination method according to claim 9, wherein the brain tumor is glioma, and the glioma is resistant to a temozolomide therapy.

### Claim 11 (depends on 1)

The determination method according to claim 1, wherein the peptide vaccine composition includes at most four peptide antigens.

### Claim 12 (depends on 1)

The determination method according to claim 1, further comprising:
evaluating a risk with respect to administration of the peptide vaccine composition based on a lymphocyte in a blood sample from the subject to obtain a risk; and
determining whether the administration of the peptide vaccine composition is canceled or not based on the risk,
wherein the lymphocyte is at least one selected from the group consisting of a CD11b+CD14+HLA-DRlow immunosuppressive monocyte, a CD3+CD4+CD45RA−T cell and a CD4+CD25+FoxP3+ cell (Treg).

### Claim 13

A method for treating a subject suffering from a brain tumor by administering a peptide vaccine composition including at least one peptide antigen, wherein the subject is a person who is determined as an eligible person for the peptide vaccine composition based on an evaluation on a risk of the subject with regard to the peptide vaccine composition; and
the evaluation is made based on at least one prognostic factor selected from the group consisting of GM-CSF, at least one SART2, MCP-1, VEGF, IL-6, IL-7, IL-10, IL-17, IL-1RA, CCL4, and haptoglobin.

### Claim 14 (depends on 13)

The treatment method according to claim 13, wherein the peptide vaccine composition includes at least two peptide antigens selected from the peptide antigen group containing SART2-93 peptide (SEQ ID NO:1), SART3-109 peptide (SEQ ID NO:2), Lck-208 peptide (SEQ ID NO:3), PAP-213 peptide (SEQ ID NO:4), PSA-248 peptide (SEQ ID NO:5), EGF-R-800 peptide (SEQ ID NO:6), MRP3-503 peptide (SEQ ID NO:7), MRP3-1293 peptide (SEQ ID NO:8), SART2-161 peptide (SEQ ID NO:9), Lck-486 peptide (SEQ ID NO:10), Lck-488 peptide (SEQ ID NO:11), PSMA-624 peptide (SEQ ID NO:12), EZH2-735 peptide (SEQ ID NO:13), and PTHrP-102 peptide (SEQ ID NO:14).

### Claim 15 (depends on 1)

A kit for use in the determination method according to claim 1, containing a reagent for measuring at least one prognostic factor selected from the group consisting of GM-CSF, at least one SART2, MCP-1, VEGF, IL-6, IL-7, IL-10, IL-17, IL-1RA, CCL4, and haptoglobin.

### Claim 16 (depends on 6)

The determination method according to claim 6, wherein the at least one SART2 peptide includes either one or both of SART2-93 peptide (SEQ ID NO:1) and SART2-161 peptide (SEQ ID NO:9).

### Claim 17 (depends on 13)

The treatment method according to claim 13, wherein the brain tumor is glioma and the glioma is resistant to a temozolomide therapy.
